1				2
				3														4											5
		6																				7			8
												9												10
11							12
				13																							14
																	15			16
							17
																18
19
																	20							21				22
					23			24
																										25	26
			27														28			29
			30
																								31
																								32
	33							34
			35																										36
37
																						38				39
								40
																41								42
							43
																												44
45										46											47
																		48
	49																	50								51

Across 1. ERYTHROMYCIN; COMBINED WITH A CURIFORM MUSCLE RELAXANT WILL INTERUPT NERE TRANSMISSIONCAUSING APNEA; MAY CAUSE RESPIRATORY PARALYSIS 6. THE FORM THAT APPOINTS SOMEONE ELSE TO MANAGE HEALTH TREATMENT DECISION IF PT IS UNABLE 10. SURGICAL REPAIR 11. CRITICAL VALUES IS GREATER THAT 70 SEC. AND IS MONITORED IN PT ON HEPARIN THERAPY AND TO DETECT DEFICIENCIES IN FACTOR VIII,IX 13. PROTRUSION OF INTERNAL ORGANS THROUGH THE SURGICAL WOUND 16. PT SHOULD HAVE SURGERY ; FAILURE IS NOT CATASTROPHIC 17. MAY BE NEEDED TO KEEP BLOOD GLUCOSE NORMAL THERFORE INFUSED AS A DRIP DURING SURGERY 18. RELIEVES OR REDUCES PAIN 19. CHLOROMAZINE; INCREASES HYPOTENSIVE ACTION OF ANESTHESIA;REDUCE HICCUP 20. REPLACES MALFUNCTIONING STRUCTURES 24. CONFIRMS DIAGNOSIS 25. CRUSHING 28. SUTURE 30. RESTORE FUNCTION OR APPEARANCE 32. SURGICAL DECISION REST W/ PT 34. CRITICAL VALUES INCLUDE LESS THAT 40 MG/DL AND GREATER THAN 400MG.DL AND IS USUALLY ASSSESSED PRIOR TO MORNING MEAL AND MORE FREQUENTLY IN DIABETICS 37. LEVOTHYROXINE SODIUM; MAY NEEDED IV POST OP TO MAINTAIN THYRIOD AND PREVENT THYROTOXICOSIS 40. SURGICAL REMOVAL 41. RISK OF HIGH DEGREE B/C OF PROLONGED ANESTHESIA, BLOOD LOSS, OR INCISION INTO VITAL ORGANS 42. YOU SHOULD STOP 4-8WKS B/F SURGERYTO PREVENT RESPIRATORY PROBLEMS 43. WARFARE;INCREASE THE RISK OF BLEEDING DURING INTRA AND POST OP; MAY PRECIPATE HEMORRHAGE 45. SURGICAL PUNCTURE 46. LEVEL SHOULD BE UNDER 200 MG/DL 47. BYPRODUCT OF HEME CATABOLISM FROM AGED RED BLOOD CELLS; VALUES GREATER THAN 15MG/DL ARE CONSIDERED CRITICAL 49. SPECIFIC INSTRUCTIONS ON WHAT THE CLIENT DOES NOT WANT 50. SURGICAL BINDING 51. PERMANENT OR SEMI-PERMANANT OPENING

Down 2. THIS TESTING IS DONE FOR SURGICAL PATIENTS WHO MAY BE AT RISK FOR EXCESSIVE LOSS DURING SURGERY 3. NUTRIENT THAT INCREASE THE RATE OF WOUND HEALING 4. DONE TO EVALUATE RESPONSE TO COUMADIN DERIVED ANTICOAGULANT THERAPIES AND TO IDENTIFY DISORDERS OF CLOTTING FACTORS II,V,VII AND X / VITAMIN K DEFICIENCY 5. INCISION 7. PROCEDURE PERFORMED IMMEDIATELY TO SAVE THE LIFE OF THE PT. W/O DELAY 8. TO TAKE OUT A DISEASED PART 9. ENZYMES PRODUCED IN HIGHEST CONC BY THE LIVER, WITH LOWER AMOUNTS IN KIDNEYS, HEART, SKELETAL MUSCLE;W/AST FOR LIVER FUNCTION 11. PRE-OP,INTRA-OP, POST-OP = 12. INHIBITS PLATELET AGGREGATION AND SHOULD BE STOPPED 7-10 DAYS PREOP 14. SURGICAL FIXATION 15. THE FORM THAT APPOINTS SOMEONE ELSE TO MANAGE HEALTH TREATMENT DECISION IF PT IS UNABLE 21. FORMERLY KNOWN AS SGOT, THIS ENZYME IS PRODUCED IN LARGE AMOUNTS BY THE LIVER, MODERATE BY THE MYOCARDIAL CELLS AND SMALL AMOUNTS BY THE KIDNEYS, PANCREAS AND BRAIN 22. PHENELZINE SULFATE; MAY CAUSE HYPOTENSIVE ACTION ,CONTRIBUTING TO SHOCK 23. DIAZEPAM; CAUSES ANXIETY, TENSION, ANS SEIZURES IF SUDDEN WITHDRAWAL; USING DURING SURGERY TO REDUCE ANXIETY 26. PERFERRED TREATMENT FOR A CONDITION THAT IS NOT IMINENTLY LIFE THREATENING ; FEW WKS- MONTHS 27. HORMONE SECRETED BY THE PLACENTA AT 8-10 DAYS AFTER CONCEPTION 29. MAY BE NEEDED INTRA AND POST OP TO GUIDE AGAINST SURGERY 31. PRENISONE; CARDIO-VASCULAR COLLAPSE CAN OCCUR IF DISCONTINUED SUDDENLY 33. PARTIAL OR COMPLETE SEPARATION OF WOUNDS 35. BEGINS WHEN THE DECISION FOR SURGERY IS MADE AND ENDS WHEN PT IS PLACED ON OPERATING TABLE 36. PT. REQUIRES PROMPT ATTENTION 24-30 HRS 38. HYDROCHLOROTHIAZIDE; MAY CAUSE RESPIRATORY DEPRESSION FROM ELCTROLYTE IMBALANCE 39. ACT OF VEIWING 44. RISK OF LOW DEGREE/ LITTLE RISK WITH FEW COMPLICATION 48. ENZYMES THAT CATALYZES THE REVERSIBLE CONVERSIONOF LACTATE TO PYRUVATE W/IN CELLS; INDICATOR OF TISSUE DAMAGE IN LIVER, LUNG AND KIDNEY DISORDERS